NeuroPace, Inc. revised earnings guidance for the full year 2023. For the year, the company Increased total revenue guidance to range between $59 million and $61 million, representing growth of 30% to 34% over 2022, as compared to prior guidance of between $52 million and $54 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.17 USD | -4.56% | -3.88% | -20.76% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.76% | 235M | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023